Mpox vaccination

What you need to know about mpox (formerly called monkeypox) vaccine in Massachusetts.

Table of Contents

How to obtain vaccine

JYNNEOS vaccine is available to individuals who live or work in Massachusetts and meet the CDC’s eligibility criteria. See above for eligibility details.

Administration of JYNNEOS is available at any one of the designated health care locations listed below. Healthcare providers are responsible to perform exposure assessment to confirm eligibility prior to scheduling an appointment for a vaccine. Vaccination sites designated below may also offer vaccination on a walk-in basis (no appointment required).

Please contact sites first to confirm that walk-in vaccinations are offered.

Vaccine appointments are available from these clinics:


As of October 3, 2022, vaccination will be available to individuals who live or work in Massachusetts and meet the CDC’s current eligibility criteria, which have recently expanded to include individuals at potential risk for mpox in addition to those with possible recent exposure to an individual with mpox.

Persons eligible for post-exposure vaccination (PEP) include: 

  • People who had known or suspected exposure to someone with mpox
  • People who had a sex partner in the past 2 weeks who was diagnosed with mpox

         In addition, CDC now allows for pre-exposure vaccination (PrEP) of persons at risk for mpox which includes:

  • Gay, bisexual, and other men who have sex with men, and transgender or nonbinary people (including adolescents who fall into any of these categories) who, in the past 6 months, have had:
    • A new diagnosis of one or more sexually transmitted diseases (e.g., chlamydia, gonorrhea, syphilis); or
    • More than one sex partner.
  • People who have had any of the following in the past 6 months:
    • Sex at a commercial sex venue; or,
    • Sex in association with a large public event in a geographic area where mpox transmission is occurring.
    • Sex in exchange for money or other items
  • People who are sexual partners of people with the above risks.
  • People who anticipate experiencing any of the above scenarios.
  • People with HIV infection or other causes of immunosuppression who have had recent or anticipate potential mpox exposure.
  • People who work in settings where they may be exposed to mpox:
    • People who work with orthopoxviruses in a laboratory

When an individual at risk requests vaccine, they will not be asked which of these criteria applies. It is sufficient to say that they consider themselves to be at risk for mpox.

Information for health care providers

Visit information for health care providers for details on smallpox/mpox vaccine (JYNNEOS™) administration, eligibility, and availability in Massachusetts. 

About the JYNNEOS vaccine

When properly administered before or soon after exposure, vaccines can help protect against mpox.

The vaccine most commonly used for preventing mpox infection is JYNNEOS (also known as Imvamune or Imvanex), which has been licensed by the U.S. Food and Drug Administration (FDA).

In the United States, there is now ample supply of JYNNEOS available through the commercial market. Effective July 1, 2024, state supplied JYNNEOS doses (NDC: 50632-0001-02) may only be administered to individuals who are 18 years of age, irrespective of insurance status, or adults (19 years of age and older) who are uninsured/underinsured. 

State-supplied JYNNEOS supply will be limited from May-August 2024, outside of the doses currently at provider sites. Limited quantities of state-supplied JYNNEOS will remain available upon request by provider sites to meet patient demand during this period. Increased access of state-supplied JYNNEOS will be available in Fall 2024.

The standard regimen for JYNNEOS involves a subcutaneous (SQ) route of administration with an injection volume of 0.5mL. An alternative regimen involving intradermal (ID) administration with an injection volume of 0.1mL may be used under an Emergency Use Authorization (EUA) in people 18 years and over.

  • Both the standard (0.5mL SQ) and the alternative (0.1mL ID) regimen have been found to be effective for mpox prevention.
  • There is currently adequate supply of JYNNEOS vaccine. Therefore, clinicians can preferentially administer JYNNEOS via the subcutaneous route.

People who get vaccinated should continue to protect themselves from infection by avoiding close, skin-to-skin contact, including intimate contact, with someone who has mpox.

Data on JYNNEOS can be found on the CDC website

Help Us Improve  with your feedback

Please do not include personal or contact information.